FY2024 EPS Estimates for GH Research Lowered by Analyst

GH Research PLC (NASDAQ:GHRS) – Research analysts at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for GH Research in a research report issued to clients and investors on Monday, January 27th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.80) per share for the year, down from their prior forecast of ($0.76). HC Wainwright currently has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for GH Research’s Q4 2024 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($0.95) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($0.94) EPS and FY2028 earnings at ($0.49) EPS.

Separately, Canaccord Genuity Group dropped their target price on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 18th.

GH Research Stock Performance

NASDAQ GHRS opened at $9.43 on Wednesday. The business has a fifty day moving average price of $8.38 and a 200 day moving average price of $8.92. The company has a market cap of $490.64 million, a P/E ratio of -11.94 and a beta of 0.84. GH Research has a one year low of $6.00 and a one year high of $14.99.

Institutional Inflows and Outflows

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. grew its stake in GH Research PLC (NASDAQ:GHRS) by 1.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,686,689 shares of the company’s stock after acquiring an additional 85,000 shares during the quarter. RA Capital Management L.P. owned about 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).